Table of contents

• Male Menopause Treatment at a Glance
• What Is Male Menopause Treatment?
• Who Is a Good Candidate for Male Menopause Treatment?
• How Is Male Menopause Treatment Performed?
• Why Visit Korea for Male Menopause Treatment?
• Key Information for International Patients
• Which Are the Best Clinics in Korea for Male Menopause Treatment?
• Male Menopause Treatment From Start to Finish
• Alternatives to Male Menopause Treatment
• How Can I Prepare for Male Menopause Treatment?
• Aftercare Advice

Considering treatment in Korea? Everything you need to know e.g. — how to avoid scams, visas, interpreters, recovery tips — in our Medical Tourism Master Guide. Plan with confidence in minutes, not weeks!

Last updated: September 2026

Male Menopause Treatment at a Glance

• What it treats — “Male menopause” treatment is medical evaluation and ongoing management of confirmed male hypogonadism, not a one-time anti-aging procedure; testosterone therapy may be prescribed as gel, injection, or oral testosterone undecanoate where available.
• Diagnosis comes first — Treatment requires compatible symptoms plus two low early-morning testosterone results on separate days; fatigue, aging, low mood, or one low test alone does not establish testosterone deficiency.
• Best candidates — Appropriate candidates have persistent symptoms such as low libido, fewer spontaneous erections, unexplained anemia, or reduced muscle or bone mass, and can arrange continuing testosterone, hematocrit, symptom, and prostate-risk monitoring at home.
• Fertility limitation — Exogenous testosterone suppresses sperm production, so men trying to conceive or planning near-term fertility should seek reproductive-urology or endocrinology care, which may use hCG with or without FSH instead.
• Korea visit length — Plan about 3–5 business days to complete an assessment, two separate early-morning testosterone tests, and a results review; suspected pituitary, testicular, sleep, urinary, fertility, or cardiovascular issues can require more appointments.
• Gradual results and follow-up — There is usually no downtime beyond temporary injection-site soreness, but benefits develop gradually: libido or some mood changes may appear in 3–6 weeks, lean-mass changes in 12–16 weeks, and anemia improvement in 3–6 months; testing is needed at about 3–6 months and periodically thereafter.
• Korea-specific interpretation — Korean guidance cites a provisional total-testosterone threshold near 2.6 ng/mL, versus commonly used international thresholds of about 3.0–3.5 ng/mL; clinicians should interpret borderline results with symptoms and, when needed, free testosterone, SHBG, LH, FSH, and prolactin testing.

What Is Male Menopause Treatment?

Male menopause treatment is medical evaluation and management of male hypogonadism, a condition involving symptoms and consistently low testosterone levels. It aims to identify the cause of low testosterone and improve concerns such as reduced sexual desire, low energy, anemia, or loss of muscle mass when treatment is appropriate. It is non-surgical care that can include lifestyle treatment, treatment of underlying conditions, or monitored testosterone therapy.

Who Is a Good Candidate for Male Menopause Treatment?

• Confirmed symptomatic low testosterone — Good candidates have persistent low libido, fewer spontaneous erections, reduced sexual desire, unexplained anemia, reduced muscle or bone mass, or other compatible signs, together with repeatedly low early-morning testosterone.
• Cause needing clarification — Men whose symptoms could stem from obesity, obstructive sleep apnea, thyroid disease, high prolactin, medication effects, alcohol or substance exposure, prior anabolic-steroid use, pituitary disease, or testicular disease need a structured endocrine assessment.
• Monitoring access at home — Testosterone therapy is appropriate only when a clinician can monitor symptoms, testosterone levels, hematocrit, and prostate risk after the Korea visit.
• No near-term fertility plan — Exogenous testosterone suppresses the hormonal signals needed for sperm production. Men trying to conceive need fertility-preserving specialist care instead.

“Male menopause” is a consumer term, not a formal diagnosis. A defensible diagnosis of male hypogonadism requires compatible symptoms or signs plus consistently low testosterone on properly timed repeat testing; aging, fatigue, low mood, or one low result alone do not establish it. Do not start testosterone with known or suspected prostate or male breast cancer, an unevaluated prostate nodule, or a PSA result requiring urology review. Elevated hematocrit, untreated severe obstructive sleep apnea, severe urinary symptoms, uncontrolled heart failure, thrombophilia, or a heart attack or stroke within the previous six months require deferral or individualized specialist assessment. The evaluation must also distinguish primary testicular failure from hypothalamic-pituitary causes, particularly in younger men, men with infertility, or those with very low testosterone.

How Is Male Menopause Treatment Performed?

Management is cause-directed first. Testosterone replacement therapy (TRT) is ongoing prescription treatment for confirmed hypogonadism, not a one-time anti-aging or energy procedure.

• Cause-directed treatment — The clinician addresses reversible contributors, including obesity, sleep apnea, endocrine disorders, heavy alcohol use, contributing medicines, and anabolic-steroid exposure. This approach can be more important than testosterone replacement when low testosterone is functional or temporary.
• Transdermal testosterone gel or solution — Daily skin application provides relatively steady exposure but requires consistent use and measures to prevent transfer to partners or children through skin contact.
• Testosterone injections — Shorter-acting injections and long-acting testosterone undecanoate are selected according to clinical needs, access to monitoring, formulation availability, and ability to continue care after travel. A routine injection is outpatient and commonly causes no downtime beyond temporary injection-site soreness.
• Oral testosterone undecanoate — This is an option only where locally licensed and prescribed; suitability, availability, and travel supply cannot be assumed for international visitors.
• Fertility-preserving hormone care — Selected men with secondary hypogonadism who want fertility can need reproductive-urology or endocrinology management with hCG, sometimes combined with FSH. Clomiphene or related selective estrogen-receptor modulators are off-label options in selected cases, not interchangeable substitutes for testosterone.

Why Visit Korea for Male Menopause Treatment?

Korea-specific guidance emphasizes symptom-led diagnosis with laboratory confirmation rather than treating nonspecific midlife symptoms as “male menopause.” A Korea visit can support a focused endocrine, urologic, and metabolic work-up, but it cannot replace long-term monitoring in the patient’s home country.

• Korean diagnostic context — The Korean Society of Men’s Health and Aging (KSMHA) describes a provisional Korean total-testosterone threshold near 2.6 ng/mL, while noting that international thresholds commonly fall around 3.0–3.5 ng/mL. The difference is a reason for individualized interpretation, not a lower automatic treatment threshold, as explained in the KSMHA position statement.
• Borderline-result assessment — KSMHA recommends considering symptoms alongside laboratory findings and adding SHBG, calculated free testosterone, LH, FSH, and prolactin when total testosterone is borderline or does not match symptoms. These tests help identify secondary hypogonadism and other endocrine causes.
• Structured monitoring standard — KSMHA calls for symptom review at 3, 6, and 12 months, with testosterone and hematocrit assessment around 3–6 months after starting treatment and periodic monitoring thereafter. This makes a documented handoff plan essential for medical tourists.
• Evidence limits — There is no universally accepted definition of “male menopause” or single global testosterone cutoff. Long-term benefit-risk evidence remains incomplete, particularly for depression, diabetes prevention, and fracture prevention; Korea’s proposed threshold is explicitly provisional.

Key Information for International Patients

• Minimum practical stay — Plan 3–5 business days rather than a single appointment. This practical estimate allows an initial assessment, an early-morning fasting testosterone test, repeat morning testing on a separate day, and a results review; it is not a universal clinical minimum.
• When to stay longer — Suspected pituitary or testicular disease, fertility testing, major urinary symptoms, cardiovascular instability, or sleep-apnea assessment can require additional local appointments or a remote specialist pathway.
• Flight timing — There is no evidence-based universal no-fly interval after blood testing or a routine testosterone injection. Travel timing should instead account for feeling well after the visit, access to medicines, and the need to return for any unexpected assessment.
• Downtime and itinerary — Consultation, examination, blood sampling, and a standard injection are outpatient. Avoid scheduling an important long-haul departure immediately after an appointment if a new medicine is being discussed or an abnormal result needs review.
• Repeat visits and follow-up — Do not rely on fly-in treatment alone. Arrange a home clinician before traveling and leave Korea with the diagnosis, laboratory results, product and dose details, monitoring dates, and clear instructions for adverse effects.
• Medicine transport — Korea requires prior approval for self-treatment medicines classified as narcotic drugs or psychotropic substances. Confirm the exact testosterone product’s status, quantity, documentation, airline rules, and destination-country import and export requirements through the Ministry of Food and Drug Safety process before travel.

Travel note: A prescription issued in Korea does not guarantee that a home clinician can continue the same formulation or that it can be carried across borders. Secure continuity of care before starting TRT.

Which Are the Best Clinics in Korea for Male Menopause Treatment?

Listed below are some of the best clinics in Korea for male menopause treatment.

1. Yezak Urology

You may consider Yezak Urology for male menopause (andropause) care if you want an evaluation of age-related hormonal changes alongside sexual, urinary, metabolic, and cardiovascular health considerations. Your plan can address fatigue, mood or sexual symptoms through lifestyle measures, targeted medication, and monitored testosterone therapy when it is clinically indicated.

• URL: Yezak Urology Website
• Location: Seoul
• Andropause care:
  • Evaluation of age-related hormonal changes and symptoms such as fatigue, mood changes, and sexual concerns.
  • Lifestyle optimization, targeted medications, and monitored testosterone therapy may be incorporated when appropriate.
• Related men’s health services:
  • General health checkups cover urinary, sexual, metabolic, and cardiovascular systems, with preventive guidance and referrals based on findings.
  • Erectile dysfunction care can include PDE5 inhibitors, intracavernosal injections, vacuum devices, and shockwave therapy, while considering cardiovascular and hormonal contributors.
• Clinical setting:
  • The Apgujeong men’s health center provides surgical and non-surgical care through a multi-specialist team and describes using advanced safety systems.
  • The clinic reports more than 20 years of specialization in male enhancement and urologic care.

Male Menopause Treatment From Start to Finish

1. Pre-travel consultation — Send a complete symptom history, fertility plans, prior morning testosterone results, CBC/hematocrit and PSA history where relevant, medication and supplement list, allergy history, sleep-study records, cardiovascular records, and prior anabolic-steroid exposure. Confirm whether English communication or a virtual consultation is available.
2. Initial in-person evaluation — The clinician reviews sexual, reproductive, urinary, sleep, cardiovascular, mental-health, medicine, alcohol, and substance history. Examination is performed when indicated, including assessment for testicular, breast, prostate-risk, or pituitary-related concerns.
3. First morning blood test — Have total testosterone measured early in the morning, commonly while fasting when the clinic requests it. The clinician can add CBC/hematocrit, SHBG, calculated free testosterone, LH, FSH, prolactin, metabolic tests, or other targeted studies based on the presentation.
4. Repeat confirmation test — Return for a second early-morning testosterone measurement on a different day. A single low measurement, particularly during acute illness or disrupted sleep, should not be used alone to diagnose hypogonadism.
5. Cause and safety review — The clinician interprets symptoms and repeat results, evaluates prostate risk or PSA when appropriate, and refers for semen analysis, sleep evaluation, urology, endocrinology, or pituitary imaging when findings warrant it.
6. Treatment decision — Treat identified contributors first where possible. When confirmed hypogonadism and safety screening support TRT, discuss gel, injection, or oral testosterone undecanoate where available, including dosing, fertility effects, risks, and the home-country monitoring plan.
7. Outpatient treatment or prescription plan — A routine testosterone injection, when selected, is administered without surgery or general anesthesia. Gel, oral medication, or injection timing must be documented precisely; do not combine formulations or self-adjust doses.
8. Discharge and travel handoff — Leave with laboratory reports, diagnosis, treatment rationale, product details, instructions for missed doses and urgent symptoms, and a schedule for repeat testosterone and hematocrit testing.
9. Remote follow-up — Review symptoms and safety at roughly 3–6 months, then periodically at least annually. Reconsider or stop therapy when therapeutic testosterone levels are reached without meaningful symptom improvement, consistent with KSMHA monitoring guidance.

Alternatives to Male Menopause Treatment

The right alternative depends on the cause and the main goal. Testosterone replacement is appropriate for confirmed hypogonadism when fertility is not an immediate goal; it is not the default treatment for erectile dysfunction, fatigue, depression, infertility, or normal aging.

Treating Reversible Causes

• Sleep, weight, and medical conditions — Treat obstructive sleep apnea, obesity, thyroid disease, hyperprolactinemia, depression, systemic illness, and alcohol or substance exposure when present. Review opioids, glucocorticoids, and other potentially contributing medicines with the prescriber rather than stopping them independently.
• Tradeoff — This approach can address the actual driver of symptoms and preserve fertility, but improvement depends on the identified cause and is not immediate.

Erectile Dysfunction Care

• Focused ED assessment — Erectile dysfunction needs evaluation for vascular disease, diabetes, medication effects, psychological or relationship factors, and sleep disorders. Read more about erectile dysfunction treatment.
• PDE5 inhibitors — When clinically appropriate, these medicines are generally more reliable for erection quality than TRT alone. Testosterone can improve libido and overall sexual activity in confirmed hypogonadism, but it is not a dependable stand-alone ED treatment according to the current evidence review.

Fertility-Preserving Hormone Care

• hCG with or without FSH — Selected men with secondary hypogonadism and active fertility goals can require specialist-directed gonadotropin treatment to support sperm production.
• Off-label SERM treatment — Clomiphene can be considered in selected cases under specialist supervision. It is not appropriate for self-treatment or for every cause of low testosterone.

Urinary-Symptom Evaluation

• Prostate and bladder assessment — Severe lower-urinary-tract symptoms need evaluation before TRT. Depending on the cause, benign prostatic hyperplasia treatment can be more relevant than hormone treatment.
• Tradeoff — Treating urinary obstruction does not correct testosterone deficiency, but it addresses symptoms and safety concerns that can delay hormone therapy.

How Can I Prepare for Male Menopause Treatment?

• Collect prior records — Bring prior early-morning testosterone tests, CBC/hematocrit and PSA records where relevant, semen analyses, sleep-study results, cardiovascular reports, imaging, and previous endocrine evaluations.
• Disclose fertility plans early — State whether conception is desired now or in the near future before any testosterone prescription or injection is considered.
• List every medicine and substance — Report prescribed medicines, over-the-counter products, supplements, allergies, testosterone boosters, anabolic steroids, alcohol use, and recreational substances. Do not independently start, stop, or change testosterone, PDE5 inhibitors, anticoagulants, opioids, glucocorticoids, finasteride, or supplements for travel.
• Follow blood-test instructions — Book early-morning testing and follow the clinic’s fasting instructions. Avoid arranging the test during acute illness when possible, because illness can temporarily lower testosterone.
• Plan two morning visits — Keep the itinerary flexible for repeat testing on a separate day and for additional consultations if the results suggest prostate, sleep, fertility, cardiovascular, pituitary, or testicular concerns.
• Arrange home monitoring first — Identify the clinician who will check hematocrit, testosterone, symptoms, and prostate risk after return. Ask whether they can manage the proposed product and formulation.
• Check medicine rules before packing — Obtain written prescriptions and documentation, and verify entry, transit, airline, and destination rules for the exact product and amount.

Travel note: Do not book non-refundable onward flights until the clinic confirms whether repeat morning testing, an additional specialist review, or medicine documentation is needed.

Confirm the treating doctor’s clinic-specific testing, fasting, medication, and travel requirements; those instructions take precedence over general guidance.

Aftercare Advice

Testosterone treatment requires monitored follow-up, not recovery time or a one-off injection schedule.

• Injection-site care — Keep the area clean and observe for persistent redness, warmth, swelling, drainage, or worsening pain. Brief soreness after an injection is common; contact the clinic if it is escalating or accompanied by fever.
• Gel-transfer precautions — If prescribed a transdermal product, apply it exactly as directed, wash hands after application, cover the application area, and prevent skin-to-skin transfer to partners or children.
• Monitor response realistically — Libido and some mood symptoms can change in about 3–6 weeks; lean-mass changes take roughly 12–16 weeks, anemia response 3–6 months, and bone-density changes 6–24 months. Do not increase the dose because results feel slow.
• Complete scheduled testing — Check symptoms, testosterone level, and hematocrit at about 3–6 months after starting, then periodically at least annually. Hematocrit above 54% needs prompt prescriber-directed management.
• Report concerning changes — Contact the prescriber for worsening snoring, swelling, acne, breast tenderness or enlargement, mood changes, or urinary symptoms. Seek urgent care for chest pain, sudden shortness of breath, coughing blood, one-sided leg swelling, focal neurologic symptoms, severe allergic symptoms, or a sustained irregular heartbeat.
• Reassess benefit — Reconsider or stop treatment with the prescriber when testosterone reaches the therapeutic range without meaningful symptom benefit. TRT should not be used solely to prevent fractures, treat depression, or improve general aging-related fatigue; evidence does not establish those benefits, and trial data identified important safety signals including atrial fibrillation and acute kidney injury in some participants.

Follow the treating doctor’s individualized instructions and contact the clinic promptly when something appears wrong.